Literature DB >> 16453023

Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A.

Miho Nozaki1, Eiji Sakurai, Brian J Raisler, Judit Z Baffi, Jassir Witta, Yuichiro Ogura, Rolf A Brekken, E Helene Sage, Balamurali K Ambati, Jayakrishna Ambati.   

Abstract

VEGF-A promotes angiogenesis in many tissues. Here we report that choroidal neovascularization (CNV) incited by injury was increased by excess VEGF-A before injury but was suppressed by VEGF-A after injury. This unorthodox antiangiogenic effect was mediated via VEGFR-1 activation and VEGFR-2 deactivation, the latter via Src homology domain 2-containing (SH2-containing) tyrosine phosphatase-1 (SHP-1). The VEGFR-1-specific ligand placental growth factor-1 (PlGF-1), but not VEGF-E, which selectively binds VEGFR-2, mimicked these responses. Excess VEGF-A increased CNV before injury because VEGFR-1 activation was silenced by secreted protein, acidic and rich in cysteine (SPARC). The transient decline of SPARC after injury revealed a temporal window in which VEGF-A signaling was routed principally through VEGFR-1. These observations indicate that therapeutic design of VEGF-A inhibition should include consideration of the level and activity of SPARC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16453023      PMCID: PMC1359054          DOI: 10.1172/JCI26316

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  64 in total

1.  Vascular endothelial growth factor as a marker of tumor endothelium.

Authors:  R A Brekken; X Huang; S W King; P E Thorpe
Journal:  Cancer Res       Date:  1998-05-01       Impact factor: 12.701

2.  Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1.

Authors:  E Landgren; P Schiller; Y Cao; L Claesson-Welsh
Journal:  Oncogene       Date:  1998-01-22       Impact factor: 9.867

3.  VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries.

Authors:  M Laitinen; I Zachary; G Breier; T Pakkanen; T Häkkinen; J Luoma; H Abedi; W Risau; M Soma; M Laakso; J F Martin; S Ylä-Herttuala
Journal:  Hum Gene Ther       Date:  1997-10-10       Impact factor: 5.695

4.  Nitric oxide synthase-II is expressed in severe corneal alkali burns and inhibits neovascularization.

Authors:  F Sennlaub; Y Courtois; O Goureau
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-11       Impact factor: 4.799

5.  In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor.

Authors:  Y Cao; P Linden; D Shima; F Browne; J Folkman
Journal:  J Clin Invest       Date:  1996-12-01       Impact factor: 14.808

6.  Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization.

Authors:  C J Drake; C D Little
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

7.  Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice.

Authors:  S Hiratsuka; O Minowa; J Kuno; T Noda; M Shibuya
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

8.  Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR.

Authors:  J E Park; H H Chen; J Winer; K A Houck; N Ferrara
Journal:  J Biol Chem       Date:  1994-10-14       Impact factor: 5.157

9.  Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes.

Authors:  P F Lopez; B D Sippy; H M Lambert; A B Thach; D R Hinton
Journal:  Invest Ophthalmol Vis Sci       Date:  1996-04       Impact factor: 4.799

10.  Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells.

Authors:  B Olofsson; E Korpelainen; M S Pepper; S J Mandriota; K Aase; V Kumar; Y Gunji; M M Jeltsch; M Shibuya; K Alitalo; U Eriksson
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

View more
  38 in total

1.  Regulation of ocular angiogenesis by Notch signaling: implications in neovascular age-related macular degeneration.

Authors:  Iqbal Ahmad; Sudha Balasubramanian; Carolina B Del Debbio; Sowmya Parameswaran; Allen R Katz; Carol Toris; Robert N Fariss
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-02       Impact factor: 4.799

2.  Vascular endothelial growth factor receptor 3 signaling contributes to angioobliterative pulmonary hypertension.

Authors:  Ayser Al-Husseini; Donatas Kraskauskas; Eleanora Mezzaroma; Andrea Nordio; Daniela Farkas; Jennifer I Drake; Antonio Abbate; Quentin Felty; Norbert F Voelkel
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

3.  The role of RPE cell-associated VEGF₁₈₉ in choroidal endothelial cell transmigration across the RPE.

Authors:  Haibo Wang; Pete Geisen; Erika S Wittchen; Bradley King; Keith Burridge; Patricia A D'Amore; M Elizabeth Hartnett
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-01       Impact factor: 4.799

Review 4.  The SPARC protein: an overview of its role in lung cancer and pulmonary fibrosis and its potential role in chronic airways disease.

Authors:  Sharon L I Wong; Maria B Sukkar
Journal:  Br J Pharmacol       Date:  2016-11-25       Impact factor: 8.739

5.  Anti-SPARC oligopeptide inhibits laser-induced CNV in mice.

Authors:  Hironori Uehara; Ling Luo; Jacquelyn Simonis; Nirbhai Singh; Ethan Will Taylor; Balamurali K Ambati
Journal:  Vision Res       Date:  2009-12-22       Impact factor: 1.886

6.  SPARC inhibits adipogenesis by its enhancement of beta-catenin signaling.

Authors:  Jing Nie; E Helene Sage
Journal:  J Biol Chem       Date:  2008-11-05       Impact factor: 5.157

7.  Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase.

Authors:  Junko Kami; Kimimasa Muranaka; Yasuo Yanagi; Ryo Obata; Yasuhiro Tamaki; Masabumi Shibuya
Journal:  Jpn J Ophthalmol       Date:  2008-04-30       Impact factor: 2.447

8.  SPARC functions as an inhibitor of adipogenesis.

Authors:  Jing Nie; E Helene Sage
Journal:  J Cell Commun Signal       Date:  2009-10-02       Impact factor: 5.782

9.  CCR3 is a target for age-related macular degeneration diagnosis and therapy.

Authors:  Atsunobu Takeda; Judit Z Baffi; Mark E Kleinman; Won Gil Cho; Miho Nozaki; Kiyoshi Yamada; Hiroki Kaneko; Romulo J C Albuquerque; Sami Dridi; Kuniharu Saito; Brian J Raisler; Steven J Budd; Pete Geisen; Ariel Munitz; Balamurali K Ambati; Martha G Green; Tatsuro Ishibashi; John D Wright; Alison A Humbles; Craig J Gerard; Yuichiro Ogura; Yuzhen Pan; Justine R Smith; Salvatore Grisanti; M Elizabeth Hartnett; Marc E Rothenberg; Jayakrishna Ambati
Journal:  Nature       Date:  2009-06-14       Impact factor: 49.962

10.  SPARC: a matricellular regulator of tumorigenesis.

Authors:  Shanna A Arnold; Rolf A Brekken
Journal:  J Cell Commun Signal       Date:  2009-10-07       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.